Posted 4/4/2024, 12:18:29 PM
Amylyx to Withdraw ALS Drug Relyvrio After Clinical Trial Shows No Benefit Over Placebo
- Relyvrio, a treatment for ALS, will be withdrawn from the U.S. and Canadian markets by its maker, Amylyx Pharmaceuticals
- A large clinical trial found Relyvrio did not work better than a placebo
- Relyvrio combines two drugs taurursodiol and sodium phenylbutyrate
- About 4,000 ALS patients in the U.S. have received Relyvrio since its approval in September 2022
- Amylyx said current Relyvrio patients can transition to a free drug program if they wish to continue treatment
